NasdaqCM - Nasdaq Real Time Price USD

Agenus Inc. (AGEN)

8.30

+0.88

(+11.86%)

At close: April 25 at 4:00 PM EDT

8.59

+0.29

(+3.49%)

After hours: April 25 at 7:43 PM EDT

Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting

LEXINGTON, Mass., April 24, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab ("BOT/BAL") in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) will be presented at the upcoming American Society of Clinical Oncology (ASCO) Meeting, to be held

Business Wire yesterday

AGEN
+11.86%
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

LEXINGTON, Mass., April 23, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Business Wire 2 days ago

AGEN
+11.86%
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 3 days ago

AGEN
+11.86%
REGN
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

LEXINGTON, Mass., April 12, 2024--Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high (MSS) or deficient mismatch repair (dMMR). These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus' bro

Business Wire 13 days ago

AGEN
+11.86%
Down 75%. Is Agenus Stock a Buy on the Dip?

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

Motley Fool 17 days ago

AGEN
+11.86%
Agenus Announces Reverse Stock Split of Common Stock

LEXINGTON, Mass., April 05, 2024--Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock split of its issued and outstanding common stock, which will go into effect at 12:01 a.m., Eastern Time on April 12, 2024. The reverse stock split is intended to give Agenus greater flexibility in its future financing needs and to increase the per share trading price

Business Wire 20 days ago

AGEN
+11.86%
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?

These stocks could rocket higher, but they also present significant risks.

Motley Fool 22 days ago

AGEN
+11.86%
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

Here’s the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I’m not just talking about the price of the securities themselves. Indeed, these lesser-known enterprises are relatively low priced. No, the cost comes in the fact that extreme speculation such as this involves an inverse relationship. For maximum potential upside, you typically need to absorb the minimal amount of predictability. Let’s consider blue-chip stocks. Generally, you can be profitable with

InvestorPlace last month

AGEN
+11.86%
TNXP

BFRIW
US$5.50: That's What Analysts Think Agenus Inc. (NASDAQ:AGEN) Is Worth After Its Latest Results

There's been a notable change in appetite for Agenus Inc. ( NASDAQ:AGEN ) shares in the week since its yearly report...

Simply Wall St. last month

AGEN
+11.86%
Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript

Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript March 14, 2024 Agenus Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.053. AGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Audra, […]

Insider Monkey last month

AGEN
+11.86%
Analysts Just Shaved Their Agenus Inc. (NASDAQ:AGEN) Forecasts Dramatically

The latest analyst coverage could presage a bad day for Agenus Inc. ( NASDAQ:AGEN ), with the analysts making...

Simply Wall St. last month

AGEN
+11.86%
Agenus (AGEN) Q4 2023 Earnings Call Transcript

AGEN earnings call for the period ending December 31, 2023.

Motley Fool last month

AGEN
+11.86%
Agenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline

Fast Track Designation for BOT/BAL in Colorectal Cancer and $25 Million Milestone Payment Highlight Progress

GuruFocus.com last month

AGEN
+11.86%
Agenus Reports Fourth Quarter and Full Year 2023 Results

LEXINGTON, Mass., March 14, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Business Wire last month

AGEN
+11.86%
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

LEXINGTON, Mass., March 06, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.

Business Wire last month

AGEN
+11.86%
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., March 05, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively.

Business Wire last month

AGEN
+11.86%
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

LEXINGTON, Mass., February 29, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Business Wire last month

AGEN
+11.86%
Agenus to Participate in Leerink Partners Global Biopharma Conference

LEXINGTON, Mass., February 26, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beach, Florida. The fireside chat will take place at 2:30 p.m. ET on March 11th.

Business Wire last month

AGEN
+11.86%
Favourable Signals For Agenus: Numerous Insiders Acquired Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. 2 months ago

AGEN
+11.86%
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today

The company hopes to engineer a 1-for-20 reverse stock split.

Motley Fool 2 months ago

AGEN
+11.86%
^GSPC

Performance Overview

Return	AGEN	S&P 500
YTD	-50.00%	+5.84%
1-Year	-75.70%	+22.03%
3-Year	-86.13%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Agenus Inc. (AGEN)

Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Down 75%. Is Agenus Stock a Buy on the Dip?

Agenus Announces Reverse Stock Split of Common Stock

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

US$5.50: That's What Analysts Think Agenus Inc. (NASDAQ:AGEN) Is Worth After Its Latest Results

Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript

Analysts Just Shaved Their Agenus Inc. (NASDAQ:AGEN) Forecasts Dramatically

Agenus (AGEN) Q4 2023 Earnings Call Transcript

Agenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline

Agenus Reports Fourth Quarter and Full Year 2023 Results

Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Agenus to Participate in Leerink Partners Global Biopharma Conference

Favourable Signals For Agenus: Numerous Insiders Acquired Stock

Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today

Performance Overview